Stockholm, September 30, 2021 – Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announced that Pia Gideon was elected as a new Board member at the…
Stockholm, February 2, 2021 - Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announced the completion of a private placement of 7,465 shares, corresponding…
Stockholm, January 19, 2021 - Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announced that it has been awarded funding through the Eurostars-2 program for…
Devyser, Swedish molecular diagnostics company, is pleased to announce that it has received certification for the successful completion of a Quality Management System audit under the…
Swedish genetic test developer Devyser's product for hereditary breast and ovarian cancer (HBOC) is now CE labelled and approved for diagnostic use in the EU. The kit is based on…
Swedish molecular diagnostics company Devyser, announced today at the 45th annual European Bone Marrow Transplantation (EBMT) meeting in Frankfurt, Germany, the release of a new NGS-based…
Devyser, pioneer in diagnostic kits for complex DNA testing, and Dahui Biotech, major supplier of biotech and diagnostic products, announce today the signing of a new partnership for…
Devyser announces the opening of Devyser GmbH near Frankfurt, Germany, to strengthen its local presence. Serving the German, Austrian and Swiss markets where Devyser has experienced…
Sophia Genetics, global leader in Data-Driven Medicine, and Devyser, pioneer in diagnostic kits for complex DNA testing, announce today the signing of a new partnership to simplify the…
Stockholm, Sweden, December 15, 2015 — Devyser (www.devyser.com) has raised €1,6M ($1,8M) in funding to support the launch of new cancer diagnostic products in 2016. Funds were raised…
